Live Breaking News & Updates on Patients Receiving Later Line Systemic Therapy

Dr. Noor Abuhadra discusses managing adverse events in patients receiving TRODELVY (sacituzumab govitecan), a later-line systemic therapy for metastatic triple-negative breast cancer. Shay Elkins, a patient, shares her experience with significant side effects including diarrhea, low white blood cell counts, and hair loss, while Dr. Abuhadra emphasizes the need for proactive management of these issues to maximize treatment time and maintain quality of life. ....

Metastatic Triple Negative Breast Cancer , Overcoming Challenges , Diagnosis Treatment , Adverse Events , Patients Receiving Later Line Systemic Therapy , Triple Negative Breast Cancer , Sacituzumab Govitecan , Side Effects , Blood Counts , Hair Loss , Treatment Discontinuation , Growth Factor Support , Toxicity Comparison , Quality Of Life , Diarrhea Management ,